ETC
Exchange Traded Concepts Portfolio holdings
AUM
$7.83B
1-Year Return
24.45%
This Quarter Return
+7.15%
1 Year Return
+24.45%
3 Year Return
+83.69%
5 Year Return
+131.49%
10 Year Return
–
AUM
$4.06B
AUM Growth
+$411M
(+11%)
Cap. Flow
+$232M
Cap. Flow
% of AUM
5.72%
Top 10 Holdings %
Top 10 Hldgs %
21.64%
Holding
1,420
New
288
Increased
397
Reduced
560
Closed
115
Top Buys
| 1 |
Vanguard Long-Term Bond ETF
BLV
|
+$158M |
| 2 |
iShares Core US REIT ETF
USRT
|
+$141M |
| 3 |
Technology Select Sector SPDR Fund
XLK
|
+$138M |
| 4 |
Vanguard Extended Market ETF
VXF
|
+$101M |
| 5 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$69.2M |
Top Sells
| 1 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
+$731M |
| 2 |
Goldman Sachs Access Treasury 0-1 Year ETF
GBIL
|
+$487M |
| 3 |
NVIDIA
NVDA
|
+$38.6M |
| 4 |
Verizon
VZ
|
+$19.7M |
| 5 |
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$18.9M |
Sector Composition
| 1 | Technology | 20.92% |
| 2 | Energy | 10.24% |
| 3 | Healthcare | 10.11% |
| 4 | Industrials | 5.82% |
| 5 | Consumer Discretionary | 5.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWAV
901
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $124K | ﹤0.01% |
433
-8
| -2% | -$2.28K |
|
902
Caribou Biosciences
CRBU
$178M
| $124K | ﹤0.01% |
+29,068
| New | +$124K |
|
903
RAPT Therapeutics
RAPT
$234M
| $123K | ﹤0.01% |
+825
| New | +$123K |
|
904
Nurix Therapeutics
NRIX
$684M
| $123K | ﹤0.01% |
+12,339
| New | +$123K |
|
905
Fate Therapeutics
FATE
$118M
| $122K | ﹤0.01% |
25,611
-196,990
| -88% | -$938K |
|
|
TSVT
906
DELISTED
2seventy bio
TSVT
| $122K | ﹤0.01% |
+12,036
| New | +$122K |
|
907
Repare Therapeutics
RPTX
$77.8M
| $121K | ﹤0.01% |
+11,445
| New | +$121K |
|
|
EVRI
908
DELISTED
Everi Holdings
EVRI
| $120K | ﹤0.01% |
+8,292
| New | +$120K |
|
909
Dick's Sporting Goods
DKS
$20.7B
| $120K | ﹤0.01% |
907
-288
| -24% | -$38.1K |
|
910
Pinterest
PINS
$23.8B
| $119K | ﹤0.01% |
4,367
-792
| -15% | -$21.7K |
|
911
Sutro Biopharma
STRO
$77.2M
| $119K | ﹤0.01% |
+25,611
| New | +$119K |
|
912
Karyopharm Therapeutics
KPTI
$53.8M
| $119K | ﹤0.01% |
+4,428
| New | +$119K |
|
913
Janux Therapeutics
JANX
$1.46B
| $119K | ﹤0.01% |
+10,010
| New | +$119K |
|
914
Kura Oncology
KURA
$766M
| $118K | ﹤0.01% |
+11,175
| New | +$118K |
|
|
AUTL
915
Autolus Therapeutics
AUTL
$381M
| $118K | ﹤0.01% |
+49,527
| New | +$118K |
|
916
NIO
NIO
$13.6B
| $118K | ﹤0.01% |
12,136
+509
| +4% | +$4.93K |
|
|
AGEN
917
Agenus
AGEN
$154M
| $116K | ﹤0.01% |
+3,626
| New | +$116K |
|
918
Foghorn Therapeutics
FHTX
$291M
| $116K | ﹤0.01% |
+16,471
| New | +$116K |
|
|
LTHM
919
DELISTED
Livent Corporation
LTHM
| $116K | ﹤0.01% |
4,214
+168
| +4% | +$4.61K |
|
920
NRG Energy
NRG
$31.2B
| $115K | ﹤0.01% |
+3,087
| New | +$115K |
|
921
Prelude Therapeutics
PRLD
$67.4M
| $114K | ﹤0.01% |
+25,428
| New | +$114K |
|
922
Regency Centers
REG
$13.1B
| $114K | ﹤0.01% |
1,850
-1,251
| -40% | -$77.3K |
|
923
Inspire Medical Systems
INSP
$2.45B
| $114K | ﹤0.01% |
351
-7
| -2% | -$2.27K |
|
924
Arcellx
ACLX
$4.31B
| $114K | ﹤0.01% |
+3,596
| New | +$114K |
|
925
Teck Resources
TECK
$20.4B
| $113K | ﹤0.01% |
2,692
+448
| +20% | +$18.9K |
|